Peptide Medicine 2025-2026 Update: New Approvals, New Trial Evidence, and the Same Old Hype
Asare B. Christian, MD, MPH · 2026-10-09
Peptide Medicine 2025-2026 Update: New Approvals, New Trial Evidence, and the Same Old Hype
The Short Answer
Peptide medicine's clinical story grew stronger in 2025-2026. New phase 3 trials showed peptide co-agonists producing deep weight loss and resolving fatty liver disease, and a once-weekly GLP-2 analog reduced dependence on intravenous nutrition in short bowel syndrome. At the same time, most recovery and anti-aging peptides promoted online remain unapproved and unproven. Evidence, not enthusiasm, should determine which peptides enter your care.
What the Evidence Shows
Dual-agonist peptides delivered multi-system metabolic results
The GLORY-1 phase 3 trial evaluated mazdutide, a dual GLP-1 and glucagon receptor co-agonist, in adults with obesity, achieving dose-dependent weight reductions up to 14.0 percent with improvements in blood pressure, lipids, and liver enzymes [1]. SYNCHRONIZE-MASLD tested survodutide, another dual agonist, in obesity with fatty liver disease: up to 83 percent of participants achieved resolution of hepatic steatosis alongside significant weight loss [2].
A once-weekly GLP-2 analog restored digestive independence
The STARS phase 3 trial evaluated apraglutide, a long-acting GLP-2 analog, in patients with short bowel syndrome and intestinal failure. Once-weekly treatment significantly reduced dependence on parenteral, or intravenous, nutrition and increased the number of patients achieving digestive autonomy [3]. Alongside teduglutide, it shows that peptide therapeutics with rigorous trial evidence continue to reach patients.
The pattern behind the progress
Every one of these advances came through the same route: rational design of a known endogenous peptide pathway, then dose-finding, then large randomized trials. That is how peptide medicine legitimately advances. It is also the standard that unapproved recovery and anti-aging peptides, from BPC-157 to growth hormone secretagogues, have not met.
Clinical Interpretation
For patients, this means the peptide conversation splits cleanly in two. One track is regulated, trial-tested peptide medicine, prescribed for defined indications with known risks and monitoring. The other track is compounded, unapproved peptides sold on promise, where potency, purity, sterility, and evidence are all uncertain. A physician-led practice can use the first track responsibly and should tell you honestly that the second track is experimental at best.
Limitations and Uncertainties
The new metabolic peptides carry the class's well-known gastrointestinal side effects, and long-term safety data continue to accumulate. Trials enroll selected populations, so results do not automatically transfer to every patient. Unapproved peptides have little controlled human evidence, and compounded products carry added quality-control risk.
Who This Applies To
Patients with obesity, fatty liver disease, or metabolic dysfunction may be candidates for peptide-based metabolic therapy as part of comprehensive care. Patients considering unapproved peptides deserve a candid risk discussion and physician oversight rather than casual use.
How Aether Medicine Approaches Peptide Therapy
Within our ASSESS, RESTORE, OPTIMIZE framework, peptide decisions follow evidence grading, careful sourcing, and physician oversight: assess the underlying problem first, use peptides only where evidence is proportional to the claims, and monitor response objectively, stopping what does not work.
Frequently Asked Questions
Are peptides FDA approved?
Some are. Insulin, GLP-1 medications, teduglutide, and others are peptides. Many others sold in wellness settings are not approved for human use.
Should I take BPC-157 or TB-500?
These remain unapproved with encouraging animal data and little controlled human evidence. That is different from proven medicine, and the decision requires an honest discussion of that gap.
Are the new metabolic peptides available now?
Some, like the GLP-1 class, are approved and in use. Others, like the dual agonists discussed here, are advancing through trials and are not yet routinely available.
Do peptides require monitoring?
Yes. Any peptide therapy with clinical effect can have side effects and interactions and belongs under physician supervision with objective follow-up.
Where can I get evidence-based peptide evaluation near Philadelphia?
Aether Medicine is located at 660 American Ave, #103, King of Prussia, PA 19406, serving the Main Line and Greater Philadelphia. Call 484-806-1101 to discuss a consultation.
References
- Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2411528
- Kaplan LM, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease. Nat Med. 2026. https://doi.org/10.1038/s41591-026-04479-3
- Joly F, et al. Once-weekly apraglutide reduces parenteral support in short bowel syndrome-intestinal failure: STARS phase 3 trial. Clin Gastroenterol Hepatol. 2026. https://doi.org/10.1016/j.cgh.2026.08.026
About the Author
Asare B. Christian, MD, MPH, ABPMR, ABAARM, is Founder and Medical Director of Aether Medicine, double board-certified in Physical Medicine and Rehabilitation and Anti-Aging and Regenerative Medicine, with training at Johns Hopkins and Harvard Medical School. He serves as a Voting Member of the U.S. FDA Pharmacy Compounding Advisory Committee (PCAC), term 2026-2030, where FDA-listed expertise includes cellular medicine and regenerative therapies. This federal advisory role is separate from Aether Medicine's commercial services and does not imply FDA endorsement of the practice or any therapy.
Peptides Deserve Evidence, Not Hype
If you want an evidence-based peptide evaluation in King of Prussia, the Main Line, or Greater Philadelphia, call 484-806-1101 or visit https://aethermedicine.com.
Educational information only. This article is a draft for physician review and is not individualized medical advice. Consult your physician before starting, stopping, or changing any treatment.
Curious whether a peptide is right for you? Look it up in the peptide library, then talk to a physician at Aether Medicine in King of Prussia.